Organon Valuation
Is OGN * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OGN * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OGN * (MX$343) is trading below our estimate of fair value (MX$1493.8)
Significantly Below Fair Value: OGN * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OGN *?
Key metric: As OGN * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is OGN *'s PE Ratio? | |
|---|---|
| PE Ratio | 3.1x |
| Earnings | US$1.30b |
| Market Cap | US$4.07b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 6.8x |
| PEG Ratio | -0.4x |
Price to Earnings Ratio vs Peers
How does OGN *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 61x | ||
LAB B Genomma Lab Internacional. de | 15.4x | 19.8% | Mex$24.6b |
000513 Livzon Pharmaceutical Group | 16.6x | 10.2% | CN¥29.8b |
002603 Shijiazhuang Yiling Pharmaceutical | 191.6x | 48.6% | CN¥28.5b |
PBH Prestige Consumer Healthcare | 20.2x | 5.4% | US$4.1b |
OGN * Organon | 3.1x | -7.1% | Mex$4.1b |
Price-To-Earnings vs Peers: OGN * is good value based on its Price-To-Earnings Ratio (3.1x) compared to the peer average (60.7x).
Price to Earnings Ratio vs Industry
How does OGN *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: OGN * is good value based on its Price-To-Earnings Ratio (3.1x) compared to the Global Pharmaceuticals industry average (22.6x).
Price to Earnings Ratio vs Fair Ratio
What is OGN *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 3.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OGN *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$452.87 0% | 19.7% | Mex$586.95 | Mex$344.08 | n/a | 8 |
| Nov ’25 | Mex$343.00 | Mex$458.76 +33.7% | 20.0% | Mex$608.30 | Mex$344.70 | n/a | 8 |
| Oct ’25 | Mex$356.00 | Mex$454.83 +27.8% | 19.3% | Mex$599.78 | Mex$339.87 | n/a | 8 |
| Sep ’25 | Mex$426.40 | Mex$433.91 +1.8% | 20.4% | Mex$578.55 | Mex$327.85 | n/a | 8 |
| Aug ’25 | Mex$397.00 | Mex$415.16 +4.6% | 20.6% | Mex$553.55 | Mex$295.23 | n/a | 8 |
| Jul ’25 | n/a | Mex$377.68 0% | 20.6% | Mex$503.58 | Mex$268.57 | n/a | 8 |
| Jun ’25 | n/a | Mex$377.68 0% | 20.6% | Mex$503.58 | Mex$268.57 | n/a | 8 |
| May ’25 | Mex$299.00 | Mex$370.19 +23.8% | 21.7% | Mex$476.56 | Mex$255.30 | n/a | 8 |
| Apr ’25 | Mex$279.00 | Mex$365.90 +31.1% | 22.2% | Mex$479.30 | Mex$256.77 | n/a | 8 |
| Mar ’25 | n/a | Mex$365.90 0% | 22.2% | Mex$479.30 | Mex$256.77 | n/a | 8 |
| Feb ’25 | n/a | Mex$348.19 0% | 27.0% | Mex$459.84 | Mex$204.37 | n/a | 9 |
| Jan ’25 | n/a | Mex$349.54 0% | 28.0% | Mex$464.14 | Mex$189.10 | n/a | 9 |
| Dec ’24 | Mex$195.00 | Mex$349.54 +79.3% | 28.0% | Mex$464.14 | Mex$189.10 | n/a | 9 |
| Nov ’24 | n/a | Mex$506.88 0% | 25.5% | Mex$787.79 | Mex$348.10 | Mex$343.00 | 9 |
| Oct ’24 | n/a | Mex$501.74 0% | 20.6% | Mex$741.11 | Mex$396.41 | Mex$356.00 | 9 |
| Sep ’24 | n/a | Mex$497.46 0% | 21.7% | Mex$731.31 | Mex$391.17 | Mex$426.40 | 8 |
| Aug ’24 | Mex$364.67 | Mex$475.12 +30.3% | 23.6% | Mex$720.01 | Mex$351.63 | Mex$397.00 | 8 |
| Jul ’24 | n/a | Mex$516.03 0% | 22.0% | Mex$747.95 | Mex$365.28 | n/a | 9 |
| Jun ’24 | n/a | Mex$547.21 0% | 18.7% | Mex$764.51 | Mex$408.92 | n/a | 9 |
| May ’24 | Mex$424.00 | Mex$569.36 +34.3% | 17.1% | Mex$773.14 | Mex$431.52 | Mex$299.00 | 9 |
| Apr ’24 | Mex$380.00 | Mex$624.12 +64.2% | 15.2% | Mex$815.71 | Mex$455.28 | Mex$279.00 | 10 |
| Mar ’24 | Mex$450.00 | Mex$603.71 +34.2% | 16.0% | Mex$789.30 | Mex$440.54 | n/a | 9 |
| Feb ’24 | n/a | Mex$631.36 0% | 17.5% | Mex$814.46 | Mex$454.58 | n/a | 9 |
| Jan ’24 | n/a | Mex$654.38 0% | 17.5% | Mex$844.15 | Mex$471.15 | n/a | 9 |
| Dec ’23 | n/a | Mex$621.47 0% | 15.6% | Mex$735.13 | Mex$464.29 | Mex$195.00 | 8 |
| Nov ’23 | Mex$500.00 | Mex$688.03 +37.6% | 15.7% | Mex$817.66 | Mex$498.57 | n/a | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Incyte
US$13.8b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
INCY *
US$1,486.00
7D
0%
1Y
n/a